Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics

BACKGROUND: The OSMO study assessed the efficacy of switching to mepolizumab in patients with severe eosinophilic asthma that was uncontrolled whilst receiving omalizumab. The objective of this analysis was to assess the proportion of patients achieving pre-defined improvements in up to four efficac...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Mark C., Chipps, Bradley, Munoz, Xavier, Devouassoux, Gilles, Bergna, Miguel, Smith, Steven G., Price, Robert G., Galkin, Dmitry V., Azmi, Jay, Mouneimne, Dalal, Albers, Frank C., Chapman, Kenneth R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8111733/
https://www.ncbi.nlm.nih.gov/pubmed/33971856
http://dx.doi.org/10.1186/s12931-021-01733-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8111733/
https://www.ncbi.nlm.nih.gov/pubmed/33971856
http://dx.doi.org/10.1186/s12931-021-01733-9

Ejemplares similares